Cytovance Biologics Announces the Hiring of Dr. Jeffrey Su as Vice President of Bioanalytical Development

Cytovance Biologics Announces the Hiring of Dr. Jeffrey Su as Vice President of Bioanalytical Development to Oversee a New State of the Art Lab as Part of Its Current Expansion

OKLAHOMA CITY--(BUSINESS WIRE)--Cytovance® Biologics LLC, a biopharmaceutical contract manufacturing company specializing in the production of therapeutic proteins and antibodies from mammalian cell culture, today announced the addition of Dr. Jeffrey Su as Vice President of Bioanalytical Development to its diverse and growing scientific staff. Dr. Su will head up the state of the art Bioanalytical Development laboratory supporting existing and new client needs. This lab is part of the ongoing strategic expansion of the facilities to add scientific capabilities and the 1,000L Microbial, 1,000L and 5,000L Mammalian process train capacity. "I see this addition as a key placement to meet the needs of our expansion," said Darren Head, President & CEO of Cytovance® Biologics.

The Bioanalytical Development lab will be housed in Cytovance's multi-product cGMP production facility in Oklahoma City. The 44,000 sq. ft. facility meets the latest international regulatory standards and is custom-designed for efficient and cost-effective production. Cytovance specializes in the execution of clinical production of antibody and recombinant protein products derived from cell culture at scales up to 500L (w/v) from both fed-batch and perfusion processes.

About Jeffrey Su, PhD

Jeffrey Su, PhD, has more than 17 years experience in the Pharmaceutical/Biotech industry. He has extensive experience in Research & Development, Process development, cGMP manufacturing, Analytical development and Quality systems as well as Regulatory affairs. He has successfully managed projects involving partners in the US, Asia, Canada and Europe. Before joining Cytovance, he was the VP of Operation and Product Development at Femta Pharmaceuticals in San Diego, California. Prior to his tenure at Femta, he served as the Deputy Director and Platform leader for formulation at Sanofi Pasteur. Prior to Sanofi Pasteur, Jeffrey was the Senior Director for Manufacturing and Control at CancerVax Inc. Jeffrey also worked at various companies including Dow Chemical, Tanox Inc., Pharming Healthcare Inc., Medarex, Human Genome Sciences and Roche with increasing responsibilities. Jeffrey has 25 articles in peer-reviewed journals and 16 granted patents and applications.

About Cytovance Biologics

Cytovance Biologics is a biopharmaceutical contract manufacturing company specializing in the production of therapeutic proteins and monoclonal antibodies from mammalian cell culture. An experienced management team formed the company to address the biotechnology industry's increasing needs for full-service manufacturing capacity at the clinical and early commercial scale. In addition to its cGMP manufacturing services, the company offers process development, cGMP cell banking and support services from its Oklahoma City, Oklahoma facilities. The company's approach couples considerable client-side experience with the necessary technical and operational expertise to deliver effective processes, products and the supporting know-how that meet international regulatory standards and facilitate efficient completion of clinical development. For more information on Cytovance, visit www.cytovance.com.

Suggested Articles

Preclinical-stage biotech Abpro Therapeutics wants to trial its two lead candidates for HER2-positive cancers and diabetic macular edema in 2019.

After a rough patch in 2017, the stars seem to be realigning for French CAR-T expert Cellectis, which just closed a $164 million U.S. public offering.

Investment firm Frazier Healthcare Partners has closed its 11th fund—worth $780 million—that will help established companies accelerate their growth.